Eagle Pharmaceuticals, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical products and clinical research.
The company announced in the following press that their new drug Ryanodex has been accepted for filing and granted a priority review designation by the U.S. Food and Drug Administration (FDA).
“We evaluated Ryanodex in our clinical study conducted in a real-world acute care setting, and in a well-established animal model. Clinical data showed that Ryanodex offered a clinically meaningful benefit to EHS patients when combined with traditional cooling methods, which is further supported by statistically significant results from our animal work,” said Adrian Hepner, MD, PhD, Chief Medical Officer of Eagle Pharmaceuticals. Read the full article.
Eagle Pharmaceuticals, Inc. is a pharmaceutical company engages in the provision of injectable products. Its activities include development and commercialization of pharmaceutical products for the treatment of areas such as critical care, orphan diseases, and oncology. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ. [Source: MarketWatch]
Company Website: http://www.eagleus.com